Artificial Intelligence–Based Model Identifies Potential Resistance Drivers to CAR T-Cell Therapy in MCL
Publish Date: 2026-01-08 09:08:00
Source Domain: www.onclive.com
-
AI-Based Model Analysis: Artificial intelligence (AI)–based approaches can identify drivers of resistance to CAR T-cell therapies in patients with mantle cell lymphoma (MCL), according to Dr. Fangfang Yan’s analysis during the 2025 ASH Annual Meeting.
-
Identified Resistance Drivers: The AI model revealed significant overrepresentation of immune-related processes and pinpointed the oncogene TCL1A, as well as the S100A4 and S100A6 genes, as significant contributors to resistance.
-
Potential Treatment Targets: TCL1A enhances cell survival and impairs apoptosis, while S100A4 and S100A6 are involved in cellular migration and metastasis, suggesting their role in resistance mechanisms.
-
Future Research Directions: Further studies are ongoing to validate these potential treatment targets which may help reverse resistance to CAR T-cell therapy.
-
-
Implications of Findings: Inhibition of these identified targets may overcome resistance and highlight pathways that support tumor cell growth, offering insights into why some patients develop resistance.
-
CAR T-Cell Therapy Role in MCL: CAR T-cell therapy is a crucial option for patients with relapsed or refractory MCL, particularly after failed BTK inhibitors, though resistance and treatment beyond progressive therapy remain unmet needs.
-
AI Innovations in Cancer Research: AI’s ability to process complex, high-dimensional genomic datasets helps uncover connections and patterns within resistant tumors that traditional methods may miss, contributing to overcoming resistance mechanisms.
-
AI Method Design: The AI model used in the study was designed to handle patient heterogeneity and gene interactions in resistant tumors, employing virtual experiments to identify key drivers of resistance.
In summary, the potential success of these AI-related findings could significantly affect the treatment of CAR T-cell therapy resistance in MCL.
